These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16797109)

  • 1. The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals.
    Nauta JJ; de Bruijn IA
    Vaccine; 2006 Nov; 24(44-46):6643-4. PubMed ID: 16797109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.
    Giezeman KM; Nauta J; de Bruijn IA; Palache AM
    Vaccine; 2009 Apr; 27(18):2414-7. PubMed ID: 19368782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccine 2008-2009.
    Med Lett Drugs Ther; 2008 Oct; 50(1296):77-9. PubMed ID: 18833032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunogenicity and efficacy field evaluation (1994-1995 season) of influenza vaccine in a noninstitutionalized elderly population].
    Sandrini MC; Pregliasco F; Mensi C; Giardini G; Lucchi T; Santambrogio D; Annoni G; Vergani C
    Ann Ig; 1997; 9(5):373-9. PubMed ID: 9842071
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.
    Müller D; Szucs TD
    Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis.
    Elkayam O
    Clin Dev Immunol; 2006; 13(2-4):349-51. PubMed ID: 17162376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New vaccine approaches for seasonal and pandemic influenza.
    Palache B
    Vaccine; 2008 Nov; 26(49):6232-6. PubMed ID: 18674583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.
    Belongia EA; Kieke BA; Donahue JG; Greenlee RT; Balish A; Foust A; Lindstrom S; Shay DK;
    J Infect Dis; 2009 Jan; 199(2):159-67. PubMed ID: 19086915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to win trust over flu.
    Nature; 2009 Oct; 461(7265):698. PubMed ID: 19812628
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of inactivated influenza vaccine in children.
    Wright PF
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):200-5. PubMed ID: 17055371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
    Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Vaccine; 2006 Nov; 24(44-46):6629-31. PubMed ID: 16901593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case-control study.
    Joshi AY; Iyer VN; St Sauver JL; Jacobson RM; Boyce TG
    Vaccine; 2009 Jul; 27(33):4457-61. PubMed ID: 19490957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.